Expression of Bcl-2, integrin ?3 protein in resected non-small cell lung cancer and its clinical relevance
- VernacularTitle:Bcl-2和整合素?3蛋白在非小细胞肺癌中的表达及临床意义
- Author:
Wei WANG
;
Huiqiang HUANG
;
Zhongzhe GUAN
- Publication Type:Journal Article
- Keywords:
lung neoplasm;
non-small cell lung cancer;
bcl-2;
integrin?3;
prognosis
- From:
China Oncology
2001;0(03):-
- CountryChina
- Language:Chinese
-
Abstract:
Purpose:To study the expressions and its clinical significances of bcl-2 and integrin?3 in human Non-small cell lung cancer(NSCLC)after radical surgical resection. Methods:Immunohistochemical (IHC) staining of bcl-2 and integrin?3 was performed on paraffin-embedded sections from 269 NSCLC patients who underwent surgery and were followed up for 1.1 to 122.2(median, 48.4) months postoperatively. Differences in survival rates and clinical characteristics were evaluated by SPSS10.0 statistical software packet. Results:The prevalence of bcl-2, integrin?3 and both these proteins expression in NSCLCs was 56.9%, 47.2% and 34.9%, respectively. Bcl-2 expression was seen more frequently in female NSCLCs and smaller tumors. Integrin?3 was seen more frequently in squamous carcinomas. Cox multivariate analysis showed that bcl-2 expression in stage Ⅱ NSCLC was an independent risk factor (5 years survival rate: 39.3% vs 52.1% P=0.04), and both bcl-2 and integrin ?3 positive in stage Ⅲa NSCLC are independent good factors(5 years survival rate: 34.5% vs 23.8% P=0.04). Conclusions:Bcl-2 and integrin ?3 are indicators of NSCLC biological behavior. Combined analysis of expression of these proteins in tumors may indicate the prognosis of NSCLC.
